These observations suggest that targeting MT1B—and potentially other MTs isoforms—could offer a novel strategy to counteract lipid dysregulation, inflammation, and fibrotic progression in metabolic dysfunction–associated liver diseases. This evidence concerns the gene TIMM8A and liver disorder.